BioSpace News Archive

Pharm Country

Neuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners

Neuronetics, Inc. announced a healthcare policy update from National Government Services, Inc. that increases access for patients to its NeuroStar® Advanced Therapy for Mental Health transcranial magnetic stimulation.

February 10, 2023

·

3 min read

Business

Nona Biosciences Enters into HCAb Based Antibody Discovery Collaboration Agreement with Mythic Therapeutics

Nona Biosciences announced that it has entered into a collaboration agreement with Mythic Therapeutics, a biotechnology company focused on the development of antibody-drug conjugate-based therapies for the treatment of a wide range of cancers.

February 10, 2023

·

2 min read

Nykode Therapeutics Announces Collaboration with The GOG Foundation, Inc. to Conduct the VB-C-04 Trial in Advanced Cervical Cancer

Nykode Therapeutics ASA announced a collaboration with the GOG Foundation, Inc. to conduct a clinical trial of VB10.16 in combination with an immune checkpoint inhibitor for the treatment of advanced cervical cancer in the U.S.

February 10, 2023

·

7 min read

Business

Conformis Provides Business Update and Reports Preliminary Results for Fourth Quarter and Full-Year 2022Company Launches New Advertising Campaign

Conformis, Inc., an orthopedic medical device company that features personalized knee and hip replacement products, provided a business update and reported preliminary financial results for the fourth quarter and year ended December 31, 2022.

February 10, 2023

·

7 min read

Business

Sensient Technologies Corporation Reports Results for the Quarter Ended December 31, 2022

Sensient Technologies Corporation reported consolidated revenue of $348.7 million in this year’s fourth quarter compared to $340.4 million in last year’s fourth quarter.

February 10, 2023

·

10 min read

HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities

HanAll Biopharma Co., Ltd. announced that it is investing in Interon Laboratories, Inc., a US-based biotechnology company focusing on discovering and developing innovative treatments for brain diseases.

February 10, 2023

·

4 min read

Drug Development

VST-BIO Announces Successful Preclinical Trials in Ischemic Stroke

VST-Bio Corp. presented data from a recent large animal study performed by VST-Bio and Yale University demonstrating that a single iv bolus of VST-002 led to meaningful reduction in brain damage and improved function in an advanced model of ischemic stroke.

February 10, 2023

·

2 min read

Business

Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022

Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the “Company,” “New Ayala,” “we,” “us” or “our”) (OTCQX: ADXS), a clinical-stage oncology company, today announces financial results for the fiscal year ended October 31, 2022.

February 10, 2023

·

10 min read

Business

IQVIA Reports Fourth-Quarter and Full-Year 2022 Results; Issues Full-Year 2023 Guidance

IQVIA Holdings Inc., a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, reported financial results for the quarter ended December 31, 2022.

February 10, 2023

·

22 min read

Pharm Country

In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer

Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”) today announced initial results evaluating the synergy of HSB-1216 with immune checkpoint inhibitors in KRAS G12C-mutated non-small cell lung cancer (NSCLC) cells, Calu-1, with Pembrolizumab, an anti-PD-1 antibody.

February 10, 2023

·

4 min read